Determining superior first-line therapy in metastatic bladder cancer

The ideal first-line treatment of cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC) remains unknown pending results of randomized trials. Although mUC tumours are sensitive to chemotherapy, response durations are short. A new retrospective study provides data on the effectiveness of first-line PD-1/PD-L1 inhibitors compared with carboplatin-based chemotherapy in this…

Read the full article here

Related Articles